KEYNOTE-590

NCT03189719 📎

Regimen

Experimental
pembrolizumab + cisplatin/5-FU
Control
placebo + cisplatin/5-FU

Population

Previously untreated locally advanced or metastatic esophageal cancer (ESCC or adenocarcinoma) or Siewert type 1 GEJ cancer, regardless of PD-L1

Key finding

ESCC+CPS>=10 mOS 13.9 vs 8.8 mo (HR 0.57, 95% CI 0.43-0.75, p<0.0001); all pts mOS 12.4 vs 9.8 mo (HR 0.73, p<0.0001); PFS in all 6.3 vs 5.8 mo (HR 0.65, p<0.0001)

Source: PMID 34454674

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.63)